Augment Injectable Bone Graft

Augment Injectable Bone Graft is a biologic combination product consisting of recombinant human platelet-derived growth factor-BB (rhPDGF-BB), beta-tricalcium phosphate (β-TCP), and bovine type I collagen. Developed by BioMimetic Therapeutics (later acquired by Wright Medical and then Stryker), it is designed as an osteoinductive and osteoconductive alternative to autologous bone graft. The active component, rhPDGF-BB, is a potent mitogen and chemoattractant that binds to PDGF receptors on mesenchymal stem cells, osteoblasts, and fibroblasts to stimulate cellular proliferation and bone formation. The β-TCP serves as a porous, resorbal scaffold for new bone ingrowth, while the collagen component provides a matrix that allows for an injectable delivery format. It is primarily indicated for use in ankle and hindfoot arthrodesis and for the treatment of osseous periodontal defects.

Brand names

Augment Injectable Bone GraftAugment InjectableGEM 21SGEM21SGEM-21S

Other names

recombinant human platelet-derived growth factor-BB + beta-tricalcium phosphate + collagenrhPDGF-BB + beta-TCP + collagenrhPDGF-BB/beta-TCP/collagenrhPDGF-BB/beta-TCP-collagen matrix